Bone Biologics Corp Warrants (BBLGW)
$14.50
$0.00 (0.00%)As on 23-Jun-2026 09:30EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
10 Years Aggregate
CFO
$-39.09 Mln
EBITDA
$-56.07 Mln
Net Profit
$-65.93 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bone Biologics Corp Warrants (BBLGW)
| -- | -11.8 | -- | -- | 20.0 | -- | -- |
|
BSE Sensex*
| -8.4 | 2.8 | 4.7 | -5.5 | 7.2 | 8.0 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Bone Biologics Corp Warrants (BBLGW)
| 901.3 | 21,677.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 |
|
BSE Sensex
| 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Bone Biologics Corp Warrants (BBLGW)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which... provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Read more
-
CEO & President
Mr. Jeffrey Frelick
-
CEO & President
Mr. Jeffrey Frelick
-
Headquarters
Burlington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Bone Biologics Corp Warrants (BBLGW)
What is the current share price of Bone Biologics Corp Warrants (BBLGW) Today?
The share price of Bone Biologics Corp Warrants (BBLGW) is $14.50 (NASDAQ) as of 23-Jun-2026 09:30 EDT. Bone Biologics Corp Warrants (BBLGW) has given a return of 19.96% in the last 3 years.
What is the current PB & PE ratio of Bone Biologics Corp Warrants (BBLGW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-28.74
|
33.92
|
|
2023
|
-0.20
|
0.62
|
|
2022
|
0.00
|
0.00
|
|
2021
|
-0.02
|
0.00
|
What is the 52 Week High and Low of Bone Biologics Corp Warrants (BBLGW)?
The 52-week high and low of Bone Biologics Corp Warrants (BBLGW) are Rs 21.00 and Rs 11.00 as of 25-Jun-2026.
What is the market cap of Bone Biologics Corp Warrants (BBLGW)?
Bone Biologics Corp Warrants (BBLGW) has a market capitalisation of -- as on 18-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bone Biologics Corp Warrants (BBLGW)?
Before investing in Bone Biologics Corp Warrants (BBLGW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.